Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure. Valturna combines in a single pill valsartan, an angiotensin receptor blocker, with aliskiren, the only approved direct renin inhibitor. Valturna is the first therapy to target two points within the renin angiotensin …
Read More »FDA approves new statin drug
Pitavastatin (Livalo, Kowa Pharmaceuticals), a HMG-CoA reductase inhibitor, was approved as a primary treatment for hypercholesterolemia and combined dyslipidemia. This new medication has a unique cyclopropyl group on its base structure, giving it the potential for greater LDL clearance and the reduction of plasma cholesterol. The manufacturer also said that …
Read More »NEW PRODUCT! The Solo™ Insulin Dispensing Patch
Diabetes in Control is the first to present the Solo product information to the diabetes community. The FDA approved the Solo MicroPump for sale in the US on July 28th, The Solo MicroPump will be the smallest, lightest, most discreet full-featured insulin pump in the market. In addition, it will offer …
Read More »New Product:FDA Approves Aliskiren/HCTZ Antihypertensive Pill for First-Line Use
The US Food and Drug Administration has approved a new indication for a single-tablet combination of the renin inhibitor aliskiren (Tekturna® HCT) and the diuretic hydrochlorothiazide for the first-line treatment of hypertension in patients likely to require multiple medications to achieve their blood pressure goals. The combination tablet previously was …
Read More »FDA Approves ACTOplus met(R) XR Tablets issue 470
FDA Approves ACTOplus met(R) XR Tablets for the Treatment of Type 2 Diabetes Another “not new” drug, but new combination added to the arsenal for treating diabetes. Takeda Pharmaceuticals North America, Inc., has announced that the FDA approved an extended-release version of the combination medication ACTOplus met(R) (pioglitazone HCl and …
Read More »Old Drug, New Trick – Cycloset
FDA Approves A New First In Class Diabetes Drug – Cycloset™ People with Type 2 diabetes may soon get a very different treatment approach
Read More »Generex Biotechnology Announces Successful Phase III Study Data for Generex Oral-lyn(tm)
Generex Biotechnology announced today the successful Phase III study data for their buccal oral insulin product, Oral-lyn™. The product’s non-inferiority to injectable meal-time (prandial) insulin appears to be real and repeatable. Update on Oral-lyn
Read More »Worst Diet Promotions Of 2008 Snag, 20th Annual Slim Chance Awards
Worst diet promotions of 2008 snag 20th Annual Slim Chance Awards- Each year the Healthy Weight Network evaluates all the fad diets and programs and selects the worst of the worst. Check out this years list.
Read More »silver cloud crocs
Made with Croslite Ag+™ which is nano-Silver ceramic crystals acombined with Croslite™. This creates a material which is naturally anti-microbial, effectively killing harmful strains of bacteria and fungi which are routinely at issue with foot infections. These crocs can even have an orthotic placed in them. To learn more about …
Read More »MB07803 A First In Class Drug To Inhibit Fbpase Starts Clinical Trials
First in Class Drug for Diabetes enters Phase 2b Clinical Testing. Metabasis announced that MB07803 which is designed to regulate glucose production in the liver by inhibiting an enzyme known as fructose 1,6- bisphosphatase (FBPase), a key component of the gluconeogenesis pathway is starting clinical trials. This means yet another …
Read More »